Background: It has recently been shown that commercial air travel triggers hypoxic pulmonary vasoconstriction and modestly increases pulmonary artery pressure in healthy passengers. There is large interindividual variation in hypoxic pulmonary vasoreactivity, and some passengers may be at risk of developing fl ight-induced pulmonary hypertension, with potentially dangerous consequences. This study sought to determine whether it is possible for a susceptible passenger to develop pulmonary hypertension in response to a routine commercial fl ight. Case Report: Using in-fl ight echocardiography, a passenger was studied during a 6-h commercial fl ight from London to Dubai. The passenger was generally well and frequently traveled by air, but had been diagnosed with Chuvash polycythemia, a genetic condition that is associated with increased hypoxic pulmonary vasoreactivity. Hematocrit had been normalized with regular venesection. During the fl ight, arterial oxygen saturation fell to a minimum of 96% and systolic pulmonary artery pressure (sPAP) rapidly increased into the pulmonary hypertensive range. The in-fl ight increase in sPAP was 50%, reaching a peak of 45 mmHg. Discussion: This study has established that an asymptomatic but susceptible passenger can rapidly develop in-fl ight pulmonary hypertension even during a medium-haul fl ight. Prospective passengers at risk from such responses, including those who have cardiopulmonary disease or increased hypoxic pulmonary vasoreactivity, could benefi t from prefl ight evaluation with a hypoxia altitude simulation test combined with simultaneous echocardiography (HAST-echo). The use of in-fl ight supplementary oxygen should be considered for susceptible individuals, including all patients diagnosed with Chuvash polycythemia.
U SING IN-FLIGHT echocardiography, we recently established that the mild hypoxia of a commercial aircraft cabin modestly increases pulmonary artery pressure in healthy passengers ( 11 ) . The underlying phenomenon of hypoxic pulmonary vasoconstriction varies greatly between individuals, and highly sensitive passengers could be susceptible to large adverse responses during air travel. The clinical syndrome of acute cor pulmonale has been reported in airline passengers ( 6 , 14 ) and pulmonary hypertensive responses could contribute to in-fl ight cardiac emergencies, which are the most common cause of fl ight diversions and in-fl ight deaths ( 3 ) . However, fl ight-induced pulmonary hypertension has not previously been demonstrated.
Chuvash polycythemia is a congenital erythrocytosis that is known to cause increased hypoxic pulmonary vasoreactivity ( 9 , 10 ) . This rare autosomal recessive disorder was originally described in the Chuvash population of Russia, but has since been reported around the world ( 10 ) . Affected individuals are homozygous for a specifi c mutation in the hypoxia-inducible factor intracellular oxygen sensing pathway, which results in activation of hypoxia-inducible factor target genes such as erythropoietin ( 10 ) . Patients usually present with symptoms of polycythemia in early adulthood or are diagnosed on family screening, and are typically asymptomatic following treatment with venesection. Chuvash polycythemia predisposes to pulmonary hypertension and is associated with early mortality ( 1 , 9 , 10 ), and patients have been shown to have increased pulmonary vascular sensitivity to hypoxia in the laboratory setting ( 9 ) . Chuvash polycythemia is not included in existing aeromedical guidelines and affected patients currently travel by air without restriction. Through measurements conducted in a passenger with Chuvash polycythemia, this study aimed to determine whether a susceptible individual can develop pulmonary hypertension during a commercial fl ight.
CASE REPORT
A 30-yr-old man with Chuvash polycythemia was studied during a 6-h commercial fl ight on a Boeing 777-300 aircraft from London to Dubai. He had been diagnosed with polycythemia at the age of 8 yr and subsequent genetic analysis had identifi ed the causative Chuvash mutation. His treatment consisted of venesection every 3 mo, which had maintained a normal hematocrit for many years. He had no other medical problems and was asymptomatic and generally well. He had once experienced an episode of dyspnea during a long-haul fl ight, but had since fl own extensively without incident. His height was 1.76 m and weight was 50 kg. At the time of the study, his hematocrit was normal, but he had profound iron defi ciency due to the regular venesection. Results of baseline venous blood analyses were: hemoglobin 14.1 g z dl
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(normal range 13.0-17.0 g z dl
), and serum transferrin 3.5 g z L 2 1 (1.8-3.6 g z L 2 1 ). The study was approved by the airline and the Oxford Tropical Research Ethics Committee, and the passenger gave written informed consent.
Pulmonary artery pressure was assessed using echocardiography. These measurements were made using a standard Doppler technique that is widely used in clinical practice and research ( 8 , 9 , 12 ) , and has been previously described for in-fl ight measurements in healthy passengers ( 11 ) . Briefl y, the maximum systolic pressure gradient across the tricuspid valve was determined using Doppler with the patient reclining in a left lateral position (Vivid i portable machine, GE Medical Systems, Hatfi eld , UK), and systolic pulmonary artery pressure (sPAP) was determined using an estimated right atrial pressure of 5 mmHg. Measurements were made immediately prefl ight, hourly in fl ight, immediately postfl ight, and then daily for 2 d. Supplementary oxygen was available should symptoms develop or sPAP exceed 50 mmHg. Each set of measurements also included arterial oxygen saturation (S p o 2 ), blood pressure, heart rate, and an echocardiographic assessment of cardiac output ( 11 ) . Aircraft cabin pressure was recorded as equivalent cabin altitude throughout the fl ight.
The passenger remained asymptomatic throughout the study. Baseline sPAP was 30 mmHg, confi rming the absence of pulmonary hypertension, for which the sPAP threshold is defi ned as 36 mmHg ( 5 ) . Cruising cabin altitude was relatively low ( Fig. 1 ) , only exceeding 5400 ft (1645 m) for the last hour and cabin hypoxia was, therefore, relatively mild. S p o 2 fell from 100% prefl ight to a minimum of 96% in fl ight, and sPAP dramatically increased into the pulmonary hypertensive range ( Fig. 1 ) . The peak sPAP was 45 mmHg, corresponding to a mean pulmonary artery pressure of approximately 30 mmHg ( 2 ). The peak increase in sPAP was 50%, considerably greater than the 20% increase observed in the previous study of healthy passengers ( 11 ) .
Heart rate, cardiac output, and blood pressure remained stable throughout the study. Minute ventilation was measured by Wright's respirometer (nSpire Health Ltd, Hertford , UK) prior to takeoff and hourly in fl ight, and increased from 11.7 L z min 2 1 to a mean of 14.1 L z min 2 1 (SD 0.8) in fl ight. End-tidal partial pressure of carbon dioxide was measured by Normocap Oxy gas analyzer (Datex Engstrom, Finland) immediately prior to takeoff and descent, and decreased from 34 mmHg to 31 mmHg in fl ight. These respiratory measurements were consistent with the increased acute hypoxic ventilatory response previously observed in patients with Chuvash polycythemia ( 9 ) .
DISCUSSION
This case report has established that commercial air travel can cause in-fl ight pulmonary hypertension. The sharp rise in sPAP observed in this study nearly breached our trigger for commencing oxygen therapy, yet air passengers are commonly exposed to greater cabin hypoxia over much longer sectors of up to 19 h. Similar responses are likely to occur in other passengers with Chuvash polycythemia ( 9 ) or with related genetic mutations that cause a similar pulmonary phenotype ( 4 ). This passenger ' s iron defi ciency may also have contributed to his excessive response -reduced iron availability increases hypoxic pulmonary vasoreactivity ( 8 , 12 ) and was recently associated with higher pulmonary artery pressures in a study of 120 patients with Chuvash polycythemia ( 7 ) . As a result of our fi ndings, this passenger has been advised to use supplementary oxygen when traveling by air, at least for longer fl ights. 
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Although based on a single case, this study has broad implications that extend beyond patients with rare genetic diseases, including the many patients with heart and lung problems who wish to fl y. Flight-induced pulmonary hypertension such as that seen in this study could exacerbate or precipitate cardiopulmonary disease and contribute to in-fl ight morbidity and even mortality. The risks are presumably greater in those with naturally higher pulmonary vascular sensitivity and those in whom pulmonary artery pressures are already elevated. Passengers with pre-existing pulmonary hypertension, for example, can often tolerate air travel well, but a signifi cant minority experience adverse effects requiring medical intervention ( 13 ) .
In the aeromedical assessment of vulnerable prospective passengers, these risks could be evaluated by combining echocardiography with a standard hypoxia altitude simulation test (HAST), in which in-fl ight responses are predicted by breathing a mildly hypoxic gas mixture ( 11 ) . HAST-echo may allow prediction of in-fl ight changes in pulmonary hemodynamics, guiding decisions regarding prescription of in-fl ight supplementary oxygen and, ultimately, fi tness to fl y. Further research is required to investigate the possible benefi ts of this approach and to confi rm that the normobaric HAST and the hypobaric hypoxia of air travel induce similar pulmonary vascular responses.
Critically ill patients undergoing aeromedical transportation may be at particular risk from pulmonary hypertensive responses, and this study's fi ndings suggest that even very mild hypoxia should be avoided in this setting. In addition to passengers and patients, this study has occupational health implications for the aviation industry. Employment as aircrew or cabin crew may be unsafe for individuals who are prone to fl ight-induced pulmonary hypertension, even in the absence of symptoms. Pre-employment screening with HAST-echo may be advisable where exaggerated hypoxic pulmonary vasoreactivity can be anticipated, such as in those diagnosed with Chuvash polycythemia or with a previous history of high altitude pulmonary edema. We conclude that hypoxic pulmonary hypertension can rapidly develop even during a medium-haul fl ight. Until further evidence is forthcoming, prefl ight evaluation with HASTecho and the provision of in-fl ight supplementary oxygen should be considered for susceptible individuals, including all prospective passengers diagnosed with Chuvash polycythemia.
